ID   YM
AC   CVCL_IU39
DR   DSMZ; ACC-948
DR   Wikidata; Q54995439
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9747876;
RX   PubMed=11572760;
RX   PubMed=11821949;
RX   PubMed=12967475;
RX   PubMed=26727417;
CC   Population: Japanese.
CC   Doubling time: 36-48 hours (PubMed=9747876); ~48 hours (DSMZ=ACC-948).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Gene fusion; HGNC; HGNC:990; BCL2 + HGNC; HGNC:5853; IGL; Name(s)=IGL-BCL2 (PubMed=12967475).
CC   Sequence variation: Gene fusion; HGNC; HGNC:1001; BCL6 + HGNC; HGNC:6006; IL21R; Name(s)=BCL6-IL21R (PubMed=11821949; PubMed=12967475).
CC   Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ=ACC-948
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 9,10
ST   D18S51: 13,14,17
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 17,19
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 12,15
ST   FGA: 24
ST   Penta D: 9,12
ST   Penta E: 5,11
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 12
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=9747876; DOI=10.1038/sj.onc.1202027;
RA   Yonetani N., Akasaka T., Akasaka H., Ohno H., Okuma M., Miura I.,
RA   Takahashi N., Miyanishi S., Okumura A., Muramatsu M., Fukuhara S.;
RT   "Molecular features of a new human lymphoma cell line carrying both
RT   BCL2 and BCL6 gene rearrangements.";
RL   Oncogene 17:971-979(1998).
//
RX   PubMed=11572760; DOI=10.1111/j.1349-7006.2001.tb01183.x; PMCID=PMC5926849;
RA   Yonetani N., Ueda C., Akasaka T., Nishikori M., Uchiyama T., Ohno H.;
RT   "Heterogeneous breakpoints on the immunoglobulin genes are involved in
RT   fusion with the 5' region of BCL2 in B-cell tumors.";
RL   Jpn. J. Cancer Res. 92:933-940(2001).
//
RX   PubMed=11821949; DOI=10.1038/sj.onc.1205099;
RA   Ueda C., Akasaka T., Kurata M., Maesako Y., Nishikori M.,
RA   Ichinohasama R., Imada K., Uchiyama T., Ohno H.;
RT   "The gene for interleukin-21 receptor is the partner of BCL6 in
RT   t(3;16)(q27;p11), which is recurrently observed in diffuse large
RT   B-cell lymphoma.";
RL   Oncogene 21:368-376(2002).
//
RX   PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x; PMCID=PMC11160262;
RA   Maesako Y., Uchiyama T., Ohno H.;
RT   "Comparison of gene expression profiles of lymphoma cell lines from
RT   transformed follicular lymphoma, Burkitt's lymphoma and de novo
RT   diffuse large B-cell lymphoma.";
RL   Cancer Sci. 94:774-781(2003).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//